Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.
Toby Andrew EyreChristopher P FoxAli BodenAdrian BloorMoez DungawallaPaneesha ShankaraRichard WentAnna H SchuhPublished in: British journal of haematology (2018)